Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia

• Status: Enrolling by invitation
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic

Criteria

Inclusion Criteria:

• Must be over the age of 18

• Must speak English as your primary language

• Must have an informant who can provide independent evaluation of functioning

• Must present with a chief complaint of progressive impairment of speech or language

• Must fulfill diagnostic criteria for Primary Progressive Aphasia

Exclusion Criteria:

• Any subject who is mute or whose speech is unintelligible will be excluded

• All subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes, and subjects meeting criteria for another neurodegenerative disease, such as amnestic Alzheimer's type dementia, dementia with Lewy bodies, behavioral variant frontotemporal dementia, progressive supranuclear palsy, and corticobasal syndrome will be excluded

• Subjects who meet criteria for PPA and have mild behavioral changes, eye movement abnormalities or mild limb apraxia but who do not meet diagnostic criteria for behavioral variant frontotemporal dementia, progressive supranuclear palsy, or corticobasal syndrome respectively, will also be excluded

• All pregnant, post-partum and breast-feeding women will be excluded

• Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, etc.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).